LATEST DISCOUNTS & SALES: PROMOTIONS

Close Notification

Your cart does not contain any items

Cancer Vaccines

Challenges and Opportunities in Translation

Adrian Bot Mihail Obrocea

$105

Hardback

Not in-store but you can order this
How long will it take?

QTY:

English
CRC Press Inc
31 March 2008
"Recent advances in immunology and biology have opened new horizons in cancer therapy, included in the expanding array of cancer treatment options, which are immunotherapies, or cancer vaccines, for both solid and blood borne cancers. Cancer Vaccines: Challenges and Opportunities in Translation is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist.

Cancer Vaccines: Challenges and Opportunities in Translation:

Critically analyzes the most promising classes of investigational immunotherapies, integrating their scientific rationale and clinical potential

Discusses ""theranostics"" as pertaining to immunotherapy, i.e., using molecular diagnostics to identify patients that would most likely benefit from a therapy

Presents the new paradigm of biomarker guided R&D and clinical development in immunotherapy of cancer

Reviews bottlenecks in translational process of immunotherapies and offers strategies to resolve them"

Edited by:   ,
Imprint:   CRC Press Inc
Country of Publication:   United States
Dimensions:   Height: 229mm,  Width: 152mm,  Spine: 20mm
Weight:   498g
ISBN:   9781420054675
ISBN 10:   1420054678
Pages:   238
Publication Date:  
Audience:   Professional and scholarly ,  Undergraduate
Format:   Hardback
Publisher's Status:   Active

ADRIAN BOT is Senior Director of Scientific Management and Acting Head of Translational Medicine at MannKind Corporation, in Valencia, California. He obtained his M.D. at the University of Medicine and Pharmacy in Timisoara, Romania and his Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York. He previously held appointments at the Scripps Research Institute and Alliance Pharmaceutical Corporation in San Diego. Dr. Bot authored more than one hundred publications and patents in oncology, vaccines, drug delivery technologies and immunotherapy. He is the Editor-in-Chief of the International Reviews of Immunology and has been on advisory boards of several organizations. MIHAIL OBROCEA is Vice President, Clinical Development, MannKind Corporation, Paramus, New Jersey. Dr. Obrocea received his M.D. from the Faculty of Medicine and Pharmacy, Bucharest, Romania. He is a medical oncologist with over 10 years of academic and industry experience in oncology clinical trials, including biologic agents, small molecules and cytotoxic agents. Dr. Obrocea has published in oncology peer-reviewed literature, and has various patents in the field of biotechnology.

See Also